Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Duck Tembusu virus inactivated vaccine (HB strain)
- Development stage
- Unknown
- Lead developer
- Beijing Sinder-vet Technology
- Modality
- Whole Inactivated Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular, Subcutaneous
01
Overview
The Duck Tembusu virus inactivated vaccine (HB strain) is a veterinary biologic developed by Youbang Pharmaceutical for the prevention and control of Duck Tembusu virus disease in domestic ducks. The vaccine utilizes the HB strain of the Duck Tembusu virus (DTMUV), which is propagated in duck embryos and subsequently inactivated using formaldehyde treatment. It is formulated as an oil-emulsion vaccine, typically using mineral oil as an adjuvant to enhance the immune response. Upon administration via intramuscular or subcutaneous injection, the vaccine induces protective humoral and cellular immunity against DTMUV. Clinical studies indicate that the vaccine provides significant protection (over 80%) against virulent virus challenge, with immunity lasting approximately 4 to 6 months. Duck Tembusu virus disease is an emerging infectious disease in waterfowl characterized by severe egg drop syndrome and neurological symptoms.
- Other names
- 鸭坦布苏病毒病灭活疫苗 (HB株)Duck Tembusu virus disease inactivated vaccine (HB strain)DTMUV inactivated vaccine (HB strain)
Beyond the preview
Go deeper on Duck Tembusu virus inactivated vaccine (HB strain).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Duck Tembusu virus inactivated vaccine (HB strain).